What is RSA?
RSA specializes in comprehensive life cycle management for radiotherapy equipment, with a particular focus on external beam linear accelerators (LINACs). Since its inception in 1995, the company has been a critical support partner for the oncology community. Its services encompass equipment maintenance, parts provision, and the logistics of removals and installations, ensuring the continued operational efficiency of vital medical technology.
How much funding has RSA raised?
RSA has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
What's next for RSA?
With substantial backing indicated by $350K, RSA is positioned for strategic expansion within the medical device service industry. The recent capital infusion of $0 suggests a focus on enhancing its service offerings, potentially expanding its geographic reach, or investing in new technologies to support radiotherapy equipment. This late-stage funding context points towards a mature company aiming to solidify its market leadership and further innovate in equipment life cycle management.
See full RSA company page